Journal of Clinical Oncology, Vol 22, No 8 (April 15), 2004: pp. 1480-1490
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.02.098
Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
R. Garcia-Carbonero,
J.G. Supko,
J. Manola,
M.V. Seiden,
D. Harmon,
D.P. Ryan,
M.T. Quigley,
P. Merriam,
J. Canniff,
G. Goss,
U. Matulonis,
R.G. Maki,
T. Lopez,
T.A. Puchalski,
M.A. Sancho,
J. Gomez,
C. Guzman,
J. Jimeno,
G.D. Demetri
From the Dana-Farber Cancer Institute and Massachusetts General Hospital, Harvard Medical School, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; and Clinical Research and Development, PharmaMar, Madrid, Spain.
Address reprint requests to George D. Demetri, MD, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Shields Warren Bldg, Room G530, 44 Binney St, Boston, MA 02115; e-mail: gdemetri{at}partners.org
PURPOSE: To assess the efficacy of the marine-derived alkaloid ecteinascidin 743 (ET-743) in patients with soft tissue sarcomas that progressed despite prior conventional chemotherapy and to characterize the pharmacokinetic profiles of ET-743 in this patient population.
PATIENTS AND METHODS: Thirty-six previously treated soft tissue sarcoma patients from three institutions received ET-743 as a 24-hour continuous intravenous (IV) infusion at a dose of 1,500 µg/m2 every 3 weeks. Pharmacokinetic studies were also performed. Patients were restaged every two cycles for response by objective criteria.
RESULTS: Objective responses were observed in three patients, with one complete response and two partial responses, for an overall response rate of 8% (95% CI, 2% to 23%). Responses were durable for up to 20 months. Two minor responses (43% and 47% tumor reduction) were observed, for an overall clinical benefit rate of 14%. The predominant toxicities were neutropenia and self-limited transaminitis of grade 3 to 4 severity in 34% and 26% of patients, respectively. The estimated 1-year time to progression and overall survival rates were 9% (95% CI, 3% to 27%) and 53% (95% CI, 39% to 73%), respectively. The maximum observed plasma concentration and total plasma clearance of ET-743 (mean ± standard deviation), 1.04 ± 0.48 ng/mL and 35.6 ± 16.2 L/h/m2, respectively, were consistent with previously reported values from phase I studies of the drug given as a 24-hour IV infusion.
CONCLUSION: ET-743 is a promising new option for the management of several histologic subtypes of sarcoma. Durable objective responses were obtained in a subset of sarcoma patients with disease progression despite prior chemotherapy. Additionally, the relatively high survival rate noted in this series of previously treated patients further justifies development of this agent.
Supported in part by a grant of the Ministerio de Educacion y Cultura, Spain (R.G.-C.), and by research support from PharmaMar, Madrid, Spain.
Preliminary results of the study were presented at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12–15, 2001.
Both R.G.-C. and J.G.S. contributed equally to this work.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Penel, A. Italiano, N. Isambert, E. Bompas, G. Bousquet, F. Duffaud, and on behalf of the French Sarcoma Group (Groupe Sarc
Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy
Ann. Onc.,
October 30, 2009;
(2009)
mdp485v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Demetri, S. P. Chawla, M. von Mehren, P. Ritch, L. H. Baker, J. Y. Blay, K. R. Hande, M. L. Keohan, B. L. Samuels, S. Schuetze, et al.
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
J. Clin. Oncol.,
September 1, 2009;
27(25):
4188 - 4196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grosso, R. Sanfilippo, E. Virdis, C. Piovesan, P. Collini, P. Dileo, C. Morosi, J. C. Tercero, J. Jimeno, M. D'Incalci, et al.
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
Ann. Onc.,
August 1, 2009;
20(8):
1439 - 1444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Chuk, F. M. Balis, and E. Fox
Trabectedin
Oncologist,
August 1, 2009;
14(8):
794 - 799.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Forouzesh, M. Hidalgo, Q. Chu, A. Mita, M. Mita, G. Schwartz, J. Jimeno, J. Gomez, V. Alfaro, C. Lebedinsky, et al.
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Clin. Cancer Res.,
May 15, 2009;
15(10):
3591 - 3599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Casali, L. Jost, S. Sleijfer, J. Verweij, J.-Y. Blay, and On behalf of the ESMO Guidelines Working Group
Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv132 - iv136.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Penel, B. N. Bui, J.-O. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, S. Taieb, M. Jimenez, et al.
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
J. Clin. Oncol.,
November 10, 2008;
26(32):
5269 - 5274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Y. Blay, M. von Mehren, B. L. Samuels, M. P. Fanucchi, I. Ray-Coquard, B. Buckley, L. Gilles, C. Lebedinsky, Y. A. Elsayed, and A. Le Cesne
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Clin. Cancer Res.,
October 15, 2008;
14(20):
6656 - 6662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Mehren, R. J. Schilder, J. D. Cheng, E. Temmer, T. M. Cardoso, F. G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R. B. Cohen
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
Ann. Onc.,
October 1, 2008;
19(10):
1802 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Guirouilh-Barbat, C. Redon, and Y. Pommier
Transcription-coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex
Mol. Biol. Cell,
September 1, 2008;
19(9):
3969 - 3981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay
ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas
Oncologist,
November 1, 2005;
10(10):
827 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Verweij
Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas?
J. Clin. Oncol.,
August 20, 2005;
23(24):
5420 - 5423.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Carbonero, J.G. Supko, R.G. Maki, J. Manola, D.P. Ryan, D. Harmon, T.A. Puchalski, G. Goss, M.V. Seiden, A. Waxman, et al.
Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
J. Clin. Oncol.,
August 20, 2005;
23(24):
5484 - 5492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
Mol. Cancer Ther.,
May 1, 2005;
4(5):
814 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, F. Marchesi, C. O. Olimpio, C. Bonardi, A. Garbi, A. Lissoni, et al.
Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production
Cancer Res.,
April 1, 2005;
65(7):
2964 - 2971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
